Workflow
启迪药业集团股份公司 关于控股股东所持公司股份被司法拍卖暨控制权拟发生变更的提示性公告

Core Points - The core event involves the judicial auction of 58,606,962 shares of Qidi Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the company") held by its controlling shareholder, Qidi Technology Service Co., Ltd. (hereinafter referred to as "Qidi Technology"), which will be transferred to Hunan Sailoxian Management Consulting Partnership (Limited Partnership) (hereinafter referred to as "Hunan Sailoxian") [2][3][5] Group 1: Shareholding Changes - The shares auctioned represent 24.47% of the company's total share capital, with the transaction price being approximately 1,007,392,612.46 yuan [5] - Following the transfer, Qidi Technology's shareholding will decrease from 63,151,413 shares (26.37%) to 4,544,451 shares (1.90%), while Hunan Sailoxian will hold 58,606,962 shares, representing 24.47% of the total [2][3] Group 2: Control and Governance Impact - This change in shareholding will result in a change of control over the company, significantly affecting its equity structure and governance [3][8] - The transaction does not trigger a mandatory tender offer, but it will lead to a change in the controlling shareholder and actual controller [3][8] Group 3: Legal and Procedural Aspects - The transfer of shares is subject to legal procedures, including the completion of the transfer registration [4][8] - The buyer, Hunan Sailoxian, must comply with relevant laws and regulations regarding shareholding and transfer restrictions, including a prohibition on selling the shares for 18 months post-acquisition [8]